Q2 2024 13F Holders as of 30 Jun 2024
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
56,260,480
-
Total 13F shares
-
6,237,289
-
Share change
-
-1,014,586
-
Total reported value
-
$4,672,274
-
Put/Call ratio
-
2.4%
-
Price per share
-
$0.75
-
Number of holders
-
40
-
Value change
-
-$801,175
-
Number of buys
-
12
-
Number of sells
-
15
Institutional Holders of Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) as of Q2 2024
As of 30 Jun 2024,
Quince Therapeutics, Inc. - Common Stock, par value $0.001 per share (QNCX) was held by
40 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
6,237,289 shares.
The largest 10 holders included
TANG CAPITAL MANAGEMENT LLC, VANGUARD GROUP INC, EPIQ Capital Group, LLC, RENAISSANCE TECHNOLOGIES LLC, BlackRock Inc., HighTower Advisors, LLC, GEODE CAPITAL MANAGEMENT, LLC, Alphabet Inc., BANK OF AMERICA CORP /DE/, and BRIDGEWAY CAPITAL MANAGEMENT, LLC.
This page lists
41
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.